Featured Publications

INOVIO is focused on rapidly bringing to market precisely designed DNA medicines to potentially treat and protect people from diseases associated with HPV, cancer, and infectious diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

EClinicalMedicine
December 2020

Immunogenicity of a DNA vaccine candidate for COVID-19

Nature Communications
May 2020

Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine — Preliminary Report

The New England Journal of Medicine
October 2017

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

The Lancet Infectious Diseases
July 2019

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

The Lancet
September 2015

Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers

The Journal of Infectious Diseases
March 2019

dMAb™ (DNA-Encoded Monocolonal Antibodies)

Title	Disease Target	Product
Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge Human Vaccines & Immunotherapeutics — December 2019	Zika	INO-A002
In Vivo Delivery of a DNA-Encoded Monoclonal Antibody Protects Non-human Primates against Zika Virus Molecular Therapy — April 2019	Zika	INO-A002
In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model Cell Reports — November 2018	Ebola
Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti–CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo Cancer Research — November 2018	CTLA-4
Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody Cancer Immunology, Immunotherapy — August 2017	Prostate Cancer
DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections npj Vaccines — July 2017	Influenza

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases